Genzyme
Biosurgery has an extensive portfolio of biotechnology products in development for the treatment of heart disease.
"This transaction delivers significant value to our shareholders and allows us to combine our portfolio of orthobiologic and
biosurgery products as well as our proprietary biomaterials pipeline with Stryker's sales and marketing teams.
Before joining Macrocure, Lankry was the finance director at Omrix Biopharmaceuticals, Ltd., a division of Ethicon
Biosurgery, a Johnson and Johnson company.
Previously, Koblish was employed as president and CEO of Orthovita, a publicly traded orthobiologics and
biosurgery medical device company.
[USPRwire, Thu Dec 11 2014] Global Markets Direct's, 'Kuros
Biosurgery AG - Product Pipeline Review - 2014', provides an overview of the Kuros
Biosurgery AG's pharmaceutical research and development focus.
The medical products business, with a portfolio of intravenous (IV) solutions, nutritional therapies, drug delivery systems, administration sets, premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based
biosurgery products, will keep the Baxter International name, continue under its current chairman and CEO Robert L Parkinson Jr.
"This transaction allows us to combine our portfolio of orthobiologic and
biosurgery products as well as our proprietary biomaterials pipeline with Stryker's sales and marketing teams.
Prior to Hologic, Densel held senior management roles at Natick, Mass.-based medical device maker Boston Scientific and Cambridge, Mass.-based Genzyme
Biosurgery, which develops product lines for osteoarthritis relief, adhesion prevention, cartilage repair and severe burn treatment.
This growth was driven by record sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, antibody therapy products, including GAMMAGARD LIQUID(TM) [Immune Globulin Intravenous (Human)] (IVIG) 10% Solution for the treatment of primary immunodeficiencies, specialty plasma therapeutics and
biosurgery products.
is engaged in the discovery and development of
biosurgery and pharmaceutical products.
Previously, Toselli served five years at Sanofi in various levels of increasing responsibility, including vice president of global medical affairs Immunology and Inflammation, Biologics Division; vice president of global medical affairs and head of the
Biosurgery Discovery Performance Unit; and vice president of global medical affairs,
biosurgery.